君实生物 · Junshi Biosciences
← News archive

· Regulatory update

Junshi reports U.S. approval of LOQTORZI for nasopharyngeal carcinoma

On October 29, Junshi reported the U.S. FDA’s October 27 approval of LOQTORZI (toripalimab-tpzi) for two indications in adults with nasopharyngeal carcinoma.

The approval covers first-line use with cisplatin and gemcitabine for metastatic or recurrent locally advanced disease, and use as a single agent for recurrent unresectable or metastatic disease progressing on or after platinum-containing chemotherapy.

Read the full company release